申请人:CELGENE CORPORATION
公开号:EP1462449A1
公开(公告)日:2004-09-29
Substituted 1,3,4-oxadiazole compounds reduce the levels of TNF alpha in a mammal. Typical embodiments are 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-5-methylisoindoline-1,3-dione and 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]isoindoline-1,3-dione.
取代的 1,3,4-恶二唑化合物可降低哺乳动物体内 TNF α 的水平。典型的实施方案是 2-[1-(3-环戊氧基-4-甲氧基苯基)-2-(1,3,4-恶二唑-2-基)乙基]-5-甲基异吲哚啉-1,3-二酮和 2-[1-(3-乙氧基-4-甲氧基苯基)-2-(1,3,4-恶二唑-2-基)乙基]异吲哚啉-1,3-二酮。